dc.contributor.author | Goodman, Z. | |
dc.contributor.author | Hindes, R. | |
dc.contributor.author | Batur, Y. | |
dc.contributor.author | Vaughan, J. | |
dc.contributor.author | Brett-Smith, H. | |
dc.contributor.author | Yurdaydin, C. | |
dc.contributor.author | Senturk, H. | |
dc.contributor.author | Boron-Kaczmarska, A. | |
dc.contributor.author | Raptopoulou-Gigi, M. | |
dc.date.accessioned | 2021-03-04T10:11:13Z | |
dc.date.available | 2021-03-04T10:11:13Z | |
dc.identifier.citation | Yurdaydin C., Senturk H., Boron-Kaczmarska A., Raptopoulou-Gigi M., Batur Y., Goodman Z., Vaughan J., Brett-Smith H., Hindes R., "Entecavir (ETV) demonstrates consistent responses throughout baseline disease and demographic subgroups for the treatment of lamivudine-refractory HBeAg(+) patients with chronic hepatitis B", 41st Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Vienna, Avusturya, 26 - 30 Nisan 2006, cilt.44 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_6bea8d69-bff2-473b-aebe-e44fd8c37a2b | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/74616 | |
dc.identifier.uri | https://doi.org/10.1016/s0168-8278(06)80512-x | |
dc.language.iso | eng | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Gastroenteroloji-(Hepatoloji) | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | GASTROENTEROLOJİ VE HEPATOLOJİ | |
dc.title | Entecavir (ETV) demonstrates consistent responses throughout baseline disease and demographic subgroups for the treatment of lamivudine-refractory HBeAg(+) patients with chronic hepatitis B | |
dc.type | Bildiri | |
dc.contributor.department | , , | |
dc.identifier.volume | 44 | |
dc.contributor.firstauthorID | 131754 | |